NEW YORK – Theranos sounded too good to be true – and it was. Truvian Sciences has heard the comparisons to Elizabeth Holmes' company and wants you to know it's different.
Despite having another blood sample-based platform making bold promises, combining three different technologies to deliver point-of-care diagnostics in the retail clinic setting, CEO Jeff Hawkins was careful to emphasize that Truvian won't be taking any shortcuts in verifying its claims.